ArticleFrontiers in oncology2026
Sevoflurane is associated with reduced EGFR-VEGF-AKT signaling in glioma tissues relative to propofol: a bioinformatics and clinical pilot study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the effects of sevoflurane on glioma-associated angiogenesis and to explore the potential mechanisms, providing preliminary experimental evidence for its possible association with molecular changes relevant to glioma angiogenesis. Methods: The GSE179004 dataset was downloaded from the GEO database. This dataset consists of three glioma samples treated with sevoflurane and three untreated control samples. Differential expression analysis was performed using the limma package (|logFC|>1, Results: A total of 1,245 DEGs were identified (918 upregulated, 327 downregulated), from which 36 candidate ARDEGs were screened. Enrichment analysis showed these ARDEGs were significantly enriched in smooth muscle cell proliferation and the PI3K-AKT pathway (adj. Conclusion: This exploratory pilot study compared sevoflurane inhalational anesthesia and propofol intravenous anesthesia in human glioma tissues. Sevoflurane reduced EGFR, VEGFA and p-AKT expression, indicating distinct regulation of the EGFR-VEGF-AKT pathway versus propofol. Notably, both agents have inherent anti-tumor and anti-angiogenic effects, so these expression changes reflect relative intergroup differences rather than absolute declines from untreated baseline. Limited by small sample size, no long-term follow-up, missing functional angiogenesis tests and no anesthesia-free controls, these findings are only hypothesis-generating and need validation in larger prospective trials with proper controls. Clinical trial registration: www.chictr.org.cn, identifier ChiCTR2400092575.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.